202 related articles for article (PubMed ID: 26193793)
1. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.
Lesterhuis WJ; Rinaldi C; Jones A; Rozali EN; Dick IM; Khong A; Boon L; Robinson BW; Nowak AK; Bosco A; Lake RA
Sci Rep; 2015 Jul; 5():12298. PubMed ID: 26193793
[TBL] [Abstract][Full Text] [Related]
2. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
3. Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy.
Kissick HT; Ireland DJ; Krishnan S; Madondo M; Beilharz MW
Immunol Cell Biol; 2012 Sep; 90(8):822-6. PubMed ID: 22349521
[TBL] [Abstract][Full Text] [Related]
4. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.
Wu L; Wu MO; De la Maza L; Yun Z; Yu J; Zhao Y; Cho J; de Perrot M
Oncotarget; 2015 May; 6(14):12468-80. PubMed ID: 25980578
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for mesothelioma: rationale and new approaches.
Reuss JE; Forde PM
Clin Adv Hematol Oncol; 2020 Sep; 18(9):562-572. PubMed ID: 33006585
[TBL] [Abstract][Full Text] [Related]
6. Molecular Network-Based Drug Prediction in Thyroid Cancer.
Xu X; Long H; Xi B; Ji B; Li Z; Dang Y; Jiang C; Yao Y; Yang J
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30641858
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
8. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and immunotherapy: mapping the road ahead.
Cook AM; Lesterhuis WJ; Nowak AK; Lake RA
Curr Opin Immunol; 2016 Apr; 39():23-9. PubMed ID: 26724433
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
[TBL] [Abstract][Full Text] [Related]
11. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.
Wang L; Amoozgar Z; Huang J; Saleh MH; Xing D; Orsulic S; Goldberg MS
Cancer Immunol Res; 2015 Sep; 3(9):1030-41. PubMed ID: 26056145
[TBL] [Abstract][Full Text] [Related]
12. Combination immune checkpoint blockade as an effective therapy for mesothelioma.
Fear VS; Tilsed C; Chee J; Forbes CA; Casey T; Solin JN; Lansley SM; Lesterhuis WJ; Dick IM; Nowak AK; Robinson BW; Lake RA; Fisher SA
Oncoimmunology; 2018; 7(10):e1494111. PubMed ID: 30288361
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
14. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy and malignant mesothelioma: clinical perspectives].
Grégoire M; Ebstein F
Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
[TBL] [Abstract][Full Text] [Related]
16. Topological network analysis of differentially expressed genes in cancer cells with acquired gefitinib resistance.
Lee YS; Hwang SG; Kim JK; Park TH; Kim YR; Myeong HS; Kwon K; Jang CS; Noh YH; Kim SY
Cancer Genomics Proteomics; 2015; 12(3):153-66. PubMed ID: 25977174
[TBL] [Abstract][Full Text] [Related]
17. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
[TBL] [Abstract][Full Text] [Related]
18. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
Røe OD; Anderssen E; Sandeck H; Christensen T; Larsson E; Lundgren S
Lung Cancer; 2010 Jan; 67(1):57-68. PubMed ID: 19380173
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint blockade: a common denominator approach to cancer therapy.
Topalian SL; Drake CG; Pardoll DM
Cancer Cell; 2015 Apr; 27(4):450-61. PubMed ID: 25858804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
